Fig. 1 · Structure

Documents & Downloads

(-)-Enitociclib ((R)-Enitociclib)

CDK9 Inhibitor

(-)-Enitociclib is a selective inhibitor of cyclin-dependent kinase 9 (CDK9), with demonstrated capacity to induce apoptosis in various cancer cell lines. By inhibiting CDK9, it effectively reduces phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase II, leading to downregulation of critical oncogenes such as MYC and MCL1. This compound exhibits significant anti-proliferative effects against MYC-positive lymphoma and multiple myeloma cells, and shows synergistic potential when combined with therapies such as Bortezomib and Lenalidomide, making it a valuable tool in hematological cancer research.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1610408-96-2
Applications CDK9 Inhibitor
Formula C19H18F2N4O2S
Molecular Weight 404.43
Synonyms (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152
SMILES
COC1=C(C2=C(F)C=NC(NC3=CC(C[S@](C)(=N)=O)=CC=N3)=C2)C=CC(F)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Added to your cart

View Cart Checkout
Loading...